RxDoctor Payments Data

Steven East

Optometrist · Lake Charles, LANPI 1164439923

Payments from drug & device makers

$3,540in general payments, 2019–2025

Across 64 payments — averaging $55.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Sun Pharmaceutical Industries Inc.$349
  • Glaukos Corporation$272
  • Optos, Inc.$242
  • Coopervision Inc.$206
  • AbbVie$187
  • plus $531 from 7 others

What the payments were for

  • Travel & lodging$81123%
  • Food & beverage$2,71177%
  • Education$181%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,540 in reported general payments places this provider in the 75th percentile of 500 optometrist providers in Louisiana.

See all optometrist providers in Louisiana

Medicare billing

Part B allowed, 2024
$116,918
Medicare patients
925
Services billed
1,232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine58$67,275
LumiganBimatoprost33$15,611
CombiganBrimonidine Tartrate/Timolol14$7,858
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol27$5,339
SimbrinzaBrinzolamide/Brimonidine Tart16$3,343
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat64$1,581
Latanoprost110$1,159
Dorzolamide-TimololDorzolamide/Timolol/Pf11$959
Tobramycin-DexamethasoneTobramycin/Dexamethasone17$854
Prednisolone Acetate17$715
Travoprost11$591
ErythromycinErythromycin Base28$307
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha28$277
Timolol Maleate28$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$187$90,744105 claims
AlconSimbrinza$1,753$3,34316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 500 optometrist providers in Louisiana.

Other optometrist in Lake Charles

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →